Open Access

Expression and correlation of miR‑124 and miR‑126 in breast cancer

  • Authors:
    • Fanfan Li
  • View Affiliations

  • Published online on: March 22, 2019     https://doi.org/10.3892/ol.2019.10184
  • Pages: 5115-5119
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The expression of micro ribonucleic acid (miR)‑124 and miR‑126 in different stages of breast cancer (BC) and their correlation were investigated to analyze the role of miR‑124 and miR‑126 in the occurrence and development of BC. BC tissues of 83 BC patients treated in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from March 2016 to January 2018 were selected as the research group, while the corresponding para‑carcinoma normal tissues were selected as the control group. The relative expression levels of miR‑124 and miR‑126 in both groups were detected via reverse transcription-quantitative polymerase chain reaction (RT‑qPCR), and the miR‑124 and miR‑126 expression asociated with clinicopathological parameters of patients and the correlation between miR‑124 and miR‑126 was analyzed. The relative expression levels of miR‑124 and miR‑126 in the research group were significantly lower than those in the control group (P<0.001). miR‑124 and miR‑126 in the research group were associated with clinicopathological parameters (clinical stage, degree of pathological differentiation and lymph node metastasis) of patients (P<0.001). According to Pearson's correlation analysis, there was a positive correlation between the relative expression levels of miR‑124 and miR‑126 in cancer tissues (r=0.497, P<0.001). The expression levels of miR‑124 and miR‑126 were downregulated in BC tissues, which were associated with clinicopathological parameters (clinical stage, degree of pathological differentiation and lymph node metastasis). There was a positive correlation between the expression levels of miR‑124 and miR‑126 in BC tissues. Thus, miR‑124 and miR‑126 may be involved in the occurrence, development, invasion and metastasis of BC, and both can be used as targeted biological indexes for treatment of BC.

References

1 

Lantz PM and Booth KM: The social construction of the breast cancer epidemic. Soc Sci Med. 46:907–918. 1998. View Article : Google Scholar : PubMed/NCBI

2 

Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA and Manson JE; Nurses' Health Study, : Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 26:1752–1758. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Houssami N, Turner RM and Morrow M: Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 165:273–283. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Pogoda K, Niwińska A, Murawska M and Pieńkowski T: Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 30:3882013. View Article : Google Scholar : PubMed/NCBI

5 

Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM, Stampfer MJ, Willett WC, et al: Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 18:1403–1409. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Slattery ML, Herrick JS, Mullany LE, Samowitz WS, Sevens JR, Sakoda L and Wolff RK: The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. Genes Chromosomes Cancer. 56:769–787. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Schueller F, Roy S, Vucur M, Trautwein C, Luedde T and Roderburg C: The Role of miRNAs in the pathophysiology of liver diseases and toxicity. Int J Mol Sci. 19:22612018. View Article : Google Scholar

8 

Wu SG, Huang YJ, Bao B, Wu LM, Dong J, Liu XH, Li ZH, Wang XY, Wang L, Chen BJ, et al: miR-508-5p acts as an anti-oncogene by targeting MESDC1 in hepatocellular carcinoma. Neoplasma. 64:40–47. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Gao W, Li W, Xiao T, Liu XS and Kaelin WG Jr: Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/-clear cell renal carcinoma. Proc Natl Acad Sci USA. 114:1027–1032. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI

11 

Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 15:284–294. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

13 

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L and Mayer M: Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 26:809–815. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Alakwaa FM, Chaudhary K and Garmire LX: Deep learning accurately predicts estrogen receptor status in breast cancer metabolomics data. J Proteome Res. 17:337–347. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, et al Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer); Ovarian Cancer Association Consortium, : Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer. 128:2063–2074. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Ye D, Li Z and Wei C: Genistein inhibits the S-phase kinase-associated protein 2 expression in breast cancer cells. Exp Ther Med. 15:1069–1075. 2018.PubMed/NCBI

17 

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 42:410–414. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Li S, Mei Z, Hu HB and Zhang X: The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 233:6679–6688. 2018. View Article : Google Scholar : PubMed/NCBI

19 

Dong LL, Chen LM, Wang WM and Zhang LM: Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer. Diagn Pathol. 10:452015. View Article : Google Scholar : PubMed/NCBI

20 

Danesh H, Hashemi M, Bizhani F, Hashemi SM and Bahari G: Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 647:73–78. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Baldassari F, Zerbinati C, Galasso M, Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia S: Screen for MicroRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4/6 and PIK3CA inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI

22 

Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, Li LC, Luo HL and Wang DL: Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-β signaling pathway. Eur Rev Med Pharmacol Sci. 21:706–714. 2017.PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, F. (2019). Expression and correlation of miR‑124 and miR‑126 in breast cancer. Oncology Letters, 17, 5115-5119. https://doi.org/10.3892/ol.2019.10184
MLA
Li, F."Expression and correlation of miR‑124 and miR‑126 in breast cancer". Oncology Letters 17.6 (2019): 5115-5119.
Chicago
Li, F."Expression and correlation of miR‑124 and miR‑126 in breast cancer". Oncology Letters 17, no. 6 (2019): 5115-5119. https://doi.org/10.3892/ol.2019.10184